# What's New: Drugs RSS Feed

- Tainted Sexual Enhancement and Energy Products FDA is notifying consumers of certain products promoted for sexual enhancement and energy have been found to contain hidden ingredients and may pose a significant health risk.
- Arize contains hidden drug ingredient The Food and Drug Administration is advising consumers not to purchase or use Arize, a product promoted and sold for sexual enhancement on various websites, including www.getarize.com, and possibly in some retail stores.
- What's New Related to Drugs Want to know what&#039;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.
- FDA Roundup: January 30, 2024 The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
- Sustain® contains hidden drug ingredients The Food and Drug Administration is advising consumers not to purchase or use Sustain®, a product promoted and sold for sexual enhancement on various websites, including www.amazon.com, and possibly in some retail stores.
- Schwinnng contains hidden drug ingredient The Food and Drug Administration is advising consumers not to purchase or use Schwinnng, a product promoted and sold for sexual enhancement on various websites, including www.amazon.com, and possibly in some retail stores.
- Drug Trials Snapshots Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent. Drug Trials Snapshots provide consumers with information about who participated in clinical trials that supported the FDA approv
- Drug Trials Snapshots: REZLIDHIA REZLIDHIA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation when the disease has come back (relapsed) or has not improved after one or more treatments (refractory).
- Novel Drug Approvals for 2022 Innovative drugs often mean new treatment options for patients and advances in health care for the American public.
- Recently Issued Guidance Documents This page lists Recently Issued CBER and Cross-Center Guidance Documents.
- Drugs@FDA Data Files Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)
- Neptune Resources, LLC Issues Voluntary Nationwide Recall of Neptune’s Fix Neptune Resources, LLC is voluntarily recalling All lots of Neptune&#039;s Fix Elixir, Neptune&#039;s Fix Extra Strength Elixir, and Neptune&#039;s Fix Tablets to the consumer level. Neptune Resources LLC&#039;s distribution channels have not reported any adverse events from the use of its products. The products are be
- Pharmaceutical Science and Clinical Pharmacology Advisory Committee Charter Pharmaceutical Science and Clinical Pharmacology Advisory Committee Charter
- New Approaches for an Integrated Nonclinical-Clinical QT/Proarrhythmic Risk Assessment - 10/15/2020 New Approaches for an Integrated Nonclinical-Clinical QT/Proarrhythmic Risk Assessment
- Biosimilars | Science and Research Learn about FDA’s latest in biosimilar science and research.
- CDERLearn Training and Education Continuing Education and Training opportunities for healthcare professionals, academia, students and consumers.
- Q&A with FDA “Q&amp;A with FDA” is a monthly podcast series that provides engaging conversation and discussion about the latest regulatory topics. In this podcast series, FDA’s Division of Drug Information will answer some of the most commonly asked questions received by FDA. Perhaps you have had the same questions
- User Fee Lists Fiscal Year (FY) 2017 GDUFA facility fees are due on October 3, 2016.
- Generic Drug Facilities, Sites and Organization Lists Generic Drug Facilities, Sites and Organization Lists
- Training Course: Achieving Data Quality and Integrity in Maximum Containment Laboratories To help address challenges associated with ensuring data quality and integrity in regulated studies conducted in BSL-4 laboratories to support MCM development, FDA and UTMB collaborate to provide an annual training course on how to meet GLP requirements in BSL-4 facilities